掻痒(Pruritus)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Pruritus Overview 8
Therapeutics Development 9
Pipeline Products for Pruritus – Overview 9
Pipeline Products for Pruritus – Comparative Analysis 10
Pruritus – Therapeutics under Development by Companies 11
Pruritus – Therapeutics under Investigation by Universities/Institutes 13
Pruritus – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Pruritus – Products under Development by Companies 17
Pruritus – Products under Investigation by Universities/Institutes 19
Pruritus – Companies Involved in Therapeutics Development 20
AlbireoPharma 20
Amorepacific Corporation 21
Cara Therapeutics, Inc. 22
Conrig Pharma ApS 23
Creabilis SA 24
ELORAC, Inc. 25
FAES Farma SA 26
GlaxoSmithKline plc 27
Helsinn Holding S.A. 28
Hydra Biosciences, Inc. 29
LEO Pharma A/S 30
Merck & Co., Inc. 31
NeRRe Therapeutics Ltd 32
Nippon Shinyaku Co., Ltd. 33
RDD Pharma Ltd. 34
Shionogi & Co., Ltd. 35
Tioga Pharmaceuticals, Inc. 36
Trevi Therapeutics, Inc. 37
Vanda Pharmaceuticals Inc. 38
Pruritus – Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
A-4250 – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
aprepitant – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
asimadoline – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ASN-008 – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
bilastine – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
C-746 – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
CR-845 – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
CRG-010 – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CT-327 – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
desloratadine – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Drugs to Target Mas-Related G-Protein Coupled Receptor for Pruritus – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
GSK-2330672 – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
nalbuphine hydrochloride ER – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
naloxone hydrochloride – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
netupitant – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
NS-141 – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
orvepitant maleate – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
PAC-14028 – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
PP-120 – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
serlopitant – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Small Molecule for Pruritus Ani – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecule to Agonize CB2 for Pruritus – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Small Molecules to Antagonize TRPV3 for Pruritus and Psoriasis – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Small Molecules to Block NaV1.7 Channel for Pain and Pruritus – Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
tradipitant – Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Pruritus – Recent Pipeline Updates 79
Pruritus – Dormant Projects 88
Pruritus – Discontinued Products 89
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 90
Disclaimer 91